683 Capital Management’s IN8bio INAB Stock Holding History

683 Capital Management’s Portfolio INAB Stock Details INAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.07M	Hold	724,637	–	–	0.06%	135
2025 Q4	$1.7M	Buy	+724,637	New	+$1.38M	0.07%	112
2025 Q1	–	Sell	-25,000	Closed	-$193K	–	195
2024 Q4	$193K	Sell	25,000 -20,010	-44%	-$176K	0.01%	212
2024 Q3	$365K	Buy	45,010 +25,316	+129%	+$459K	0.03%	110
2024 Q2	$500K	Sell	19,694 -798	-4%	-$25.6K	0.04%	106
2024 Q1	$725K	Hold	20,492	–	–	0.05%	94
2023 Q4	$848K	Buy	+20,492	New	+$655K	0.07%	94

Other funds holding INAB

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

TCBWMS

Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

683 Capital Management's INAB Position: Q1 2026 in Review

683 Capital Management held its IN8bio (INAB) position steady in Q1 2026 at 724,637 shares worth $1.07M. The position accounts for 0.06% of the portfolio, ranked #135.

683 Capital Management first reported a position in INAB in Q4 2023 and has held it in 7 quarters since. The position peaked at $1.7M in Q4 2025. 19 funds tracked by Wall St. Rank hold INAB as of Q1 2026.

683 Capital Management held 724,637 shares of IN8bio worth $1.07M as of Q1 2026.
683 Capital Management left its IN8bio share count unchanged in Q1 2026.
IN8bio made up 0.06% of 683 Capital Management's portfolio in Q1 2026, its #135 holding.
683 Capital Management first reported a position in IN8bio in Q4 2023 and has held it in 7 quarters since.
683 Capital Management's IN8bio position peaked at $1.7M in Q4 2025.
19 funds tracked by Wall St. Rank held IN8bio as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.